APG Asset Management N.V. Raises Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

APG Asset Management N.V. boosted its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 2.2% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 360,093 shares of the medical equipment provider’s stock after purchasing an additional 7,828 shares during the quarter. APG Asset Management N.V. owned approximately 0.15% of Hologic worth $24,947,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of HOLX. Price T Rowe Associates Inc. MD increased its stake in shares of Hologic by 77.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 6,297,197 shares of the medical equipment provider’s stock worth $490,931,000 after buying an additional 2,753,016 shares during the last quarter. Black Creek Investment Management Inc. grew its holdings in Hologic by 60.9% during the 2nd quarter. Black Creek Investment Management Inc. now owns 2,338,970 shares of the medical equipment provider’s stock worth $173,669,000 after acquiring an additional 885,524 shares in the last quarter. Dimensional Fund Advisors LP increased its position in shares of Hologic by 5.7% in the 2nd quarter. Dimensional Fund Advisors LP now owns 2,326,992 shares of the medical equipment provider’s stock worth $172,780,000 after purchasing an additional 124,739 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its stake in shares of Hologic by 4.0% in the 2nd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,271,603 shares of the medical equipment provider’s stock valued at $168,666,000 after purchasing an additional 87,176 shares in the last quarter. Finally, The Manufacturers Life Insurance Company lifted its position in shares of Hologic by 117.4% during the fourth quarter. The Manufacturers Life Insurance Company now owns 2,163,718 shares of the medical equipment provider’s stock worth $154,598,000 after purchasing an additional 1,168,564 shares during the last quarter. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Hologic

In related news, Director Christiana Stamoulis sold 9,039 shares of the firm’s stock in a transaction dated Wednesday, July 17th. The stock was sold at an average price of $79.50, for a total transaction of $718,600.50. Following the completion of the transaction, the director now owns 45,472 shares of the company’s stock, valued at $3,615,024. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, Director Christiana Stamoulis sold 9,039 shares of the stock in a transaction that occurred on Wednesday, July 17th. The shares were sold at an average price of $79.50, for a total transaction of $718,600.50. Following the completion of the sale, the director now directly owns 45,472 shares of the company’s stock, valued at $3,615,024. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Brandon Schnittker sold 476 shares of Hologic stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $83.11, for a total transaction of $39,560.36. Following the completion of the transaction, the insider now owns 3,735 shares in the company, valued at approximately $310,415.85. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 18,280 shares of company stock valued at $1,469,973. Corporate insiders own 1.75% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on HOLX. StockNews.com cut Hologic from a “strong-buy” rating to a “buy” rating in a research note on Friday. JPMorgan Chase & Co. upped their price target on Hologic from $91.00 to $95.00 and gave the company an “overweight” rating in a research report on Tuesday, July 30th. Stephens reaffirmed an “overweight” rating and issued a $92.00 price objective on shares of Hologic in a report on Tuesday, July 30th. Royal Bank of Canada reissued a “sector perform” rating and set a $82.00 target price on shares of Hologic in a report on Friday, August 16th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $90.00 price target on shares of Hologic in a report on Tuesday, September 17th. Four equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat.com, Hologic has an average rating of “Moderate Buy” and a consensus target price of $87.60.

Hologic Stock Performance

Shares of HOLX opened at $80.82 on Friday. The firm has a market capitalization of $18.86 billion, a PE ratio of 41.23, a P/E/G ratio of 2.58 and a beta of 0.98. The company has a quick ratio of 3.32, a current ratio of 3.99 and a debt-to-equity ratio of 0.51. The firm has a 50-day moving average price of $81.08 and a 200 day moving average price of $77.27. Hologic, Inc. has a 52-week low of $64.02 and a 52-week high of $84.67.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Monday, July 29th. The medical equipment provider reported $1.06 EPS for the quarter, beating analysts’ consensus estimates of $1.02 by $0.04. The business had revenue of $1.01 billion for the quarter, compared to analyst estimates of $1 billion. Hologic had a net margin of 17.59% and a return on equity of 19.53%. The business’s revenue for the quarter was up 2.7% on a year-over-year basis. During the same quarter last year, the business earned $0.93 earnings per share. On average, sell-side analysts anticipate that Hologic, Inc. will post 4.09 earnings per share for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.